share_log

Deepika Pakianathan Sells 121,333 Shares of Calithera Biosciences, Inc. (NASDAQ:CALA) Stock

Deepika Pakianathan Sells 121,333 Shares of Calithera Biosciences, Inc. (NASDAQ:CALA) Stock

巴基斯坦迪皮卡出售 121,333 股卡利瑟拉生物科學公司股票
Defense World ·  2023/02/02 17:51

Calithera Biosciences, Inc. (NASDAQ:CALA – Get Rating) Director Deepika Pakianathan sold 121,333 shares of the firm's stock in a transaction dated Friday, January 27th. The shares were sold at an average price of $0.39, for a total value of $47,319.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

卡利瑟拉生物科學公司（NASDAQ：卡拉-獲取評級）董事迪皮卡巴基斯坦人在 1 月 27 日（星期五）的交易中出售了該公司股票的 121,333 股。這些股票以 0.39 美元的平均價格出售，總價值為 47,319.87 美元。該交易已在向證券交易委員會提交的文件中披露，該文件可在以下位置獲得： 證券交易所網站。

Calithera Biosciences Price Performance

卡利瑟拉生物科學價格性能

NASDAQ CALA opened at $0.37 on Thursday. The firm has a market cap of $1.78 million, a P/E ratio of -0.01 and a beta of 1.31. The stock's 50-day moving average is $1.65 and its 200-day moving average is $2.63. Calithera Biosciences, Inc. has a one year low of $0.30 and a one year high of $13.38.

納斯達克卡拉星期四以 0.37 美元開市。該公司的市值為 78 萬美元，市盈率為 -0.01，測試值為 1.31。該股票的 50 天移動平均線為 1.65 美元，其 200 天移動平均線為 2.63 美元。卡利瑟拉生物科學公司擁有一年低的 0.30 美元和 13.38 美元的一年高點。

Get
取得
Calithera Biosciences
卡利瑟拉生物科學
alerts:
警報：

Calithera Biosciences (NASDAQ:CALA – Get Rating) last released its quarterly earnings results on Monday, November 14th. The biotechnology company reported ($2.01) EPS for the quarter, missing analysts' consensus estimates of ($1.99) by ($0.02). Equities analysts anticipate that Calithera Biosciences, Inc. will post -8.62 EPS for the current year.

卡利瑟拉生物科學 (NASDAQ: 卡拉-獲取評級) 上週一公佈其季度收益業績週一, 11 月 14 日.該生物技術公司報告了本季度每股收益（2.01 美元），缺少分析師的共識估計為（$1.99）（0.02 美元）。股票分析師預計，卡利瑟拉生物科學公司將在本年度發布 -8.62 每股盈利。

Institutional Investors Weigh In On Calithera Biosciences

機構投資者權衡卡利塞拉生物科學

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC raised its position in Calithera Biosciences by 36.5% in the 1st quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company's stock valued at $749,000 after buying an additional 496,100 shares during the last quarter. Vanguard Group Inc. raised its position in Calithera Biosciences by 23.4% in the 3rd quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock valued at $415,000 after buying an additional 26,800 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in Calithera Biosciences in the 1st quarter valued at approximately $404,000. Affinity Asset Advisors LLC acquired a new stake in Calithera Biosciences in the 1st quarter valued at approximately $404,000. Finally, Goldman Sachs Group Inc. raised its position in Calithera Biosciences by 143.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock valued at $50,000 after buying an additional 72,865 shares during the last quarter. Institutional investors and hedge funds own 33.73% of the company's stock.
對沖基金最近修改了他們對業務的持有情況。文藝復興技術有限責任公司在卡利塞拉生物科學的地位 36.5% 在第一季度.文藝復興技術有限責任公司現在擁有 1,853,500 股價值為 749,000 美元的生物技術公司股票，價值在上個季度額外購買 496,100 股後。先鋒集團股份有限公司在第三季度上調了 23.4% 在卡利塞拉生物科學的地位。領航集團股份有限公司現在擁有該生物技術公司股票的 141,217 股股份，價值為 415,000 美元，在上一季度額外購入 26,800 股。阿麗斯卡投資集團 L.P. 在第一季度收購了卡利塞拉生物科學的新股份，價值約為 404,000 美元。親和資產顧問有限責任公司在第一季度收購了卡利塞拉生物科學的新股份，價值約為 404,000 美元。最後, 高盛集團公司. 提出了其在卡利塞拉生物科學的地位 143.2% 在第一季度.在上一季度額外購買 72,865 股股份後，高盛集團公司現在擁有該生物技術公司的 123,739 股股票，價值為 50,000 美元。機構投資者和對沖基金擁有公司股票的 33.73％。

Analyst Upgrades and Downgrades

分析師升級和降級

Several equities analysts have weighed in on the company. LADENBURG THALM/SH SH lowered Calithera Biosciences from a "buy" rating to a "neutral" rating in a research note on Tuesday, November 15th. SVB Leerink lowered Calithera Biosciences from an "outperform" rating to a "market perform" rating in a research note on Tuesday, November 15th. Finally, StockNews.com assumed coverage on Calithera Biosciences in a research note on Monday. They issued a "hold" rating on the stock.

幾位股票分析師對該公司進行了稱重。拉登堡 THALM/SH SH 降低了卡利塞拉生物科學從「買入」評級為「中性」評級在研究報告上週二, 11 月 15 日.SVB Leerink 降低卡利塞拉生物科學從「跑贏大市」評級為「市場表現」評級在週二的研究筆記, 11 月 15 日.最後，Stocknews.com 在週一的研究筆記中承擔了卡利瑟拉生物科學的報導。他們對股票發出了「持有」評級。

Calithera Biosciences Company Profile

卡利瑟拉生物科學公司簡介

(Get Rating)

(取得評分)

Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.

Calithera Biosciences, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對腫瘤和抗癌免疫細胞中新穎和關鍵代謝途徑的小分子藥物。它提供了程序，如管道, 谷氨酰胺酶抑制劑, 和精氨酸酶抑制劑.

Read More

閱讀更多

  • Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
  • Bed Bath & Beyond Is Circling the Drain
  • Allegro Microsystems Is A Well-Positioned Semiconductor Stock
  • Scotts Miracle-Gro Hits Bottom, Reversal In Play
  • Altria is a Great Recession Stock, Long-Term Outlook Uncertain
  • Novavax Shares Jumped in January While Others Slipped
  • 獲取有關卡利瑟拉生物科學研究報告的免費副本
  • 床浴 & 超越是盤旋排水
  • Allegro 微系統是定位良好的半導體股票
  • 斯科茨奇蹟-格羅擊中底部，反轉在遊戲中
  • 阿爾特里亞是一個巨大的經濟衰退股票，長期前景不確定
  • 諾瓦克斯股價在 1 月份跳漲，而其他股票則下滑

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

接收卡利塞拉生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收有關 Calithera 生物科學及相關公司的最新新聞和分析師評級的簡要每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論